<DOC>
	<DOC>NCT00203359</DOC>
	<brief_summary>It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.</brief_summary>
	<brief_title>TNF-Alpha Inhibition for Treatment of Alzheimer's Disease</brief_title>
	<detailed_description>Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 15 study subjects for a period of one month, followed by a 5 month and a 6 month possible study extension, with serial testing of cognition and function monthly.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>NINCDSADRDA Criteria for Alzheimerâ€™s disease CT or MRI consistent with AD active infection CHF demyelinating disease uncontrolled diabetes mellitus vascular dementia clinically significant neurologic disease other than AD Hachinski &gt;4 history of lymphoma TBC wbc&lt;2500 platelets&lt;100,000 HCT&lt;30 pregnancy premenopausal, fertile not on acceptable birth control change in neuroactive medication within 4 weeks of study initiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>